Publicaciones en las que colabora con María Mar Fernández Gatta García (26)

2016

  1. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma

    British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527

2014

  1. Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 955-956, Núm. 1, pp. 93-97

2013

  1. Approaches for dosage individualisation in critically ill patients

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Núm. 11, pp. 1481-1493

  2. Tratado general de biofarmacia y farmacocinética: Volumen I: LADME. Análisis farmacocinético. Biodisponibilidad y bioequivalencia

    Síntesis

2011

  1. Aprendizaje en una farmacia virtual

    Primeras Jornadas de Innovación Docente en la Universidad de Salamanca

2010

  1. The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy

    Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585

  2. Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation

    British Journal of Clinical Pharmacology, Vol. 70, Núm. 2, pp. 201-212

2009

  1. Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis

    Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280

2005

  1. Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies

    Antimicrobial Agents and Chemotherapy, Vol. 49, Núm. 12, pp. 4934-4941

2003

  1. Predicción de la absorción de medicamentos por vía oral: aplicación de modelos "in sílico"

    Anales de la Real Academia de Medicina y Cirugía de Valladolid, Núm. 41, pp. 89-100

2002

  1. Immunosuppressive therapy for paediatric transplant patients: Pharmacokinetic considerations

    Clinical Pharmacokinetics, Vol. 41, Núm. 2, pp. 115-135

1997

  1. Population pharmacokinetics of caffeine in premature neonates

    European Journal of Clinical Pharmacology, Vol. 52, Núm. 3, pp. 211-217

1996

  1. Bayesian Forecasting in Paediatric Populations

    Clinical Pharmacokinetics, Vol. 31, Núm. 5, pp. 325-330

  2. Bayesian forecasting in paediatric populations

    Clinical Pharmacokinetics

  3. Influence of pharmacokinetic model on vancomycin peak concentration targets

    Therapeutic Drug Monitoring, Vol. 18, Núm. 2, pp. 145-148

1993

  1. Vancomycin pharmacokinetics and dosage requirements in hematologic malignancies

    Clinical Pharmacy, Vol. 12, Núm. 7, pp. 515-520

1992

  1. Dosage optimization methods applied to imipramine and desipramine in enuresis treatment

    Journal of Clinical Pharmacy and Therapeutics, Vol. 17, Núm. 1, pp. 55-59

  2. Population pharmacokinetics of imipramine in children

    European Journal of Clinical Pharmacology, Vol. 43, Núm. 1, pp. 89-92

1990

  1. The influence of clinical and pharmacological factors on enuresis treatment with imipramine.

    British Journal of Clinical Pharmacology, Vol. 30, Núm. 5, pp. 693-698

1989

  1. Prediction of Imipramine Serum Levels in Enuretic Children by a Bayesian Method

    Therapeutic Drug Monitoring, Vol. 11, Núm. 6, pp. 637-641